Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/46380
Citations
Scopus Web of ScienceĀ® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRicciardelli, C.en
dc.contributor.authorJackson, M.en
dc.contributor.authorChoong, C.en
dc.contributor.authorStahl, J.en
dc.contributor.authorMarshall, V.en
dc.contributor.authorHorsfall, D.en
dc.contributor.authorTilley, W.en
dc.date.issued2008en
dc.identifier.citationProstate, 2008; 68(8):830-838en
dc.identifier.issn0270-4137en
dc.identifier.issn1097-0045en
dc.identifier.urihttp://hdl.handle.net/2440/46380-
dc.description.abstractBACKGROUND: In this study, we investigated the expression of HER-2/neu and AR in clinically organ-confined prostate cancer to determine whether alterations in these signaling pathways contribute to the development of metastatic disease. METHODS: HER-2/neu and AR immunoreactivity were evaluated in archived prostatic tissues obtained from 53 men with clinically organ-confined disease who underwent radical prostatectomy. Associations between AR and HER-2/neu immunostaining and disease outcome were determined. RESULTS: Seventy percent (37/53) of tumors exhibited high levels of HER-2/neu immunostaining and 68% (36/53) of tumors had elevated AR levels. Patients with high levels of both HER-2/neu and AR had the highest rate of PSA failure (56%, 15/27) compared with no PSA failures amongst seven patients with low levels of both HER-2/neu and AR (log rank statistic 7.69, P = 0.021). Concurrent high levels of HER-2/neu and AR expression were significantly associated with high pathological stage (P = 0.027) and development of metastatic disease (P = 0.022). CONCLUSIONS: These findings support the notion that both the HER-2/neu and AR signaling pathways may contribute to development of metastatic disease. The subset of prostate tumors with increased HER-2/neu and AR levels may benefit from treatment strategies that target both signaling pathways.en
dc.description.statementofresponsibilityRicciardelli C, Jackson M.W, Choong C.S, Stah J, Marshall V.R, Horsfall D.J and Tilley W.D.en
dc.language.isoenen
dc.publisherWiley-Lissen
dc.subjectHumans; Prostatic Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Receptor, erbB-2; Receptors, Androgen; Prostatectomy; Immunohistochemistry; Aged; Middle Aged; Maleen
dc.titleElevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potentialen
dc.typeJournal articleen
dc.identifier.rmid0020080757en
dc.identifier.doi10.1002/pros.20747en
dc.identifier.pubid43327-
pubs.library.collectionMedicine publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidRicciardelli, C. [0000-0001-7415-1854]en
dc.identifier.orcidTilley, W. [0000-0003-1893-2626]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.